You are currently browsing the archives for the Bio-Rad Product Highlight category.

Archive for the ‘Bio-Rad Product Highlight’ Category

Bio-Rad Offers New PrimePCR™ Disease Panels for Real-Time PCR

 :: Posted by American Biotechnologist on 12-18-2013

Bio-Rad Laboratories announced the launch of more than 700 new PrimePCR human and mouse disease panels and 71 new pathway panels for real-time PCR (qPCR). The panels allow researchers to thoroughly and efficiently investigate genes known to be differentially expressed in a specified pathology or biological pathway. Bio-Rad now offers more than 1,100 panels with nearly 6,700 predesigned plate configurations, establishing Bio-Rad as the industry’s largest and most up-to-date provider of predesigned plates.

The expanded product line includes highly studied pathways such as Hedgehog and bone morphogenetic protein (BMP) signaling, as well as processes such as circadian rhythms and visual perception. In addition, disease categories span hundreds of conditions, ranging from specific cancers and neoplasms to metabolic diseases such as obesity and diabetes.

Working in collaboration with Thomson Reuters, Bio-Rad developed a plate design strategy that ensures that the most relevant gene targets are chosen for each real-time PCR panel; gene targets are weighted for differentially expressed genes and the frequency with which they appear in the peer-reviewed literature. For disease panels, Thomson Reuters referenced the diseases and their corresponding gene targets in the U.S. National Library of Medicine database.

All of the assays were designed strictly adhering to MIQE guidelines: maximum transcript coverage, minimal overlap with known single nucleotide polymorphisms, and spanning large introns where possible. In addition, all of the primer assays have been fully wet-lab validated for specificity, efficiency, and sensitivity to an unprecedented level of quality, according to Jan Hellemans, cofounder of the qPCR and bioinformatics firm Biogazelle, which worked with Bio-Rad to develop these assays.

Bio-Rad has also updated and expanded its existing predesigned pathway and collection panels to include the most scientifically relevant gene targets based on current literature and the latest bioinformatics data.

For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCR.

Bio-Rad Launches PrimePCR™ Assays for Droplet Digital™ PCR

 :: Posted by American Biotechnologist on 12-11-2013

Bio-Rad Laboratories, Inc. announced the release of its PrimePCR assays for Droplet Digital PCR systems. This release expands Bio-Rad’s current offering by an additional 46 mutation detection assays and 323 copy number assays. In addition, the existing set of gene expression qPCR primer-only assays can now be used with the recently launched QX200™ Droplet Digital PCR system, featuring EvaGreen detection capabilities.

The new ddPCR assays are the only predesigned and fully wet-lab validated assays for digital PCR, alleviating the burden placed on researchers of design and experimental optimization and offering precision and sensitivity without a standard curve. The assays enable novel research strategies and accelerate discovery for inherited disorders, cancer, and infectious diseases.

Many methods for mutation analysis offer poor selectivity and fail to detect mutation events with abundances of less than one in 100 wild-type sequences. Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules, and together with the PrimePCR mutation detection assays, can enable the detection of one mutant molecule in the background of 100,000 wild-type sequences (0.001%). Measuring these extremely low levels of mutation abundance can lead to dramatically more sensitive and less invasive diagnostics.

Current methods, including qPCR and next-generation sequencing, also lack the resolution needed to accurately analyze copy number variation (CNV). Due to their high precision and absolute measurement capability, ddPCR assays enable the quantitative discrimination required to resolve small-fold changes in gene copy numbers. ddPCR assays can also be used to detect subsequent changes in the expression of target genes.

PrimePCR ddPCR assays are available in multiple reaction sizes and are compatible with both the QX100 and QX200 platforms using the ddPCR supermix for probes.

For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCR.

Using Droplet Digital™ PCR to Quantify Levels of HIV Reservoirs

 :: Posted by American Biotechnologist on 12-04-2013

What You Don’t See Truly Matters

 :: Posted by American Biotechnologist on 11-13-2013

All gels are not created equal when it comes to protein transfer. Mini-PROTEAN® TGX™ precast gels, together with the Trans-Blot® Turbo™ transfer system, offer you a complete solution for achieving fast electrophoresis and transfer times. In addition to speed, these innovative gels deliver maximum transfer of proteins onto membranes so you don’t see proteins left behind on the gel, ensuring quality western blotting results you can count on every time.

For more information visit Bio-Rad Laboratories TGX™ precast gel page.

Bio-Rad’s Droplet Digital PCR Highlighted at ASHG Annual Meeting

 :: Posted by American Biotechnologist on 10-22-2013

More accurate and precise assessment of copy number variation (CNV), the number of copies of a particular gene that are present in a genome, may lead to improved diagnosis and therapy for cancer and other diseases including autoimmune disorders. However, current technologies to determine copy number can be inaccurate, labor intensive, or prohibitively costly, diminishing their effectiveness in clinical applications.

Using Bio-Rad Laboratories’ Droplet Digital PCR (ddPCR™) technology, researchers can rapidly, accurately, and economically determine copy number states. Groups from the University of California, Davis, and the University of Colorado School of Medicine, among others, will present promising new research results at this year’s annual meeting of the American Society of Human Genetics (ASHG), held in Boston from October 22-25, 2013.

“Since its introduction in 2011, Bio-Rad Laboratory’s ddPCR technology has demonstrated the potential to be a transformative technology based on its greater precision, reproducibility, and sensitivity than conventional approaches such as real-time PCR,” said George Karlin-Neumann, the scientific affairs director at Bio-Rad’s Digital Biology Center.

Less than two years since Bio-Rad brought digital PCR systems to the market, studies using ddPCR assays have resulted in nearly 50 peer-reviewed publications.

Using ddPCR to Improve Pediatric Care

One example of how CNV determination with ddPCR technology shows promise for clinical applications is newborn CNV screening. 22q11.2 Deletion Syndrome (22q11DS) is the most common microdeletion syndrome in humans and is associated with more than 100 different diagnostic findings including craniofacial defects, developmental delay, and autism spectrum disorders. Researchers in Dr. Flora Tassone’s lab at the University of California, Davis have developed an inexpensive, rapid, sensitive, and specific alternative to fluorescent in-situ hybridization (FISH) – the currently accepted diagnostic tool – using ddPCR technology to identify newborns with 22q11DS. At the ASHG meeting, they will demonstrate for the first time the efficacy of ddPCR in large population screening studies (Program Number 2590F).

Researchers on Dr. James Sikela’s team at the University of Colorado School of Medicine are investigating DUF1220 copy number reduction and its association with microcephaly, a neurodevelopment disorder related to pediatric brain size. They will demonstrate how ddPCR is an effective technique for determining copy numbers of highly duplicated sequences such as DUF1220 and how ddPCR may be used for similar studies in future research where array comparative genomic hybridization (aCGH) analysis or qPCR are not accurate enough (Program Number 3215F).

In addition to the research findings described above, Bio-Rad’s ddPCR technology will be showcased in 11 other presentations. For more information, visit Bio-Rad’s booth at ASHG (booth #839). Bio-Rad will also be hosting an ASHG lunch workshop on Thursday, October 24 at 12:30 PM in room 211 as well as a hospitality suite on Thursday, October 24 at 7:45 PM at the New England Aquarium, 1 Central Wharf in Boston, featuring presentations from UC Davis and Harvard Medical School researchers. Please visit booth #839 for further details.